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ABSTRACT In May this year ten new countries joined the existing European Union
(EU) member states after long and complex accession negotiations. This article examines
preparations for accession that were made in the area of illicit drug policy and discusses
both their effectiveness and possible limitations. In the areas of drug trafficking and
production and the exchange of information between member states some concrete policy
measures have been almost directly transferable to new member states, largely due to the
high degree of cooperation between existing member states in these areas. However, in the
more controversial areas of harm reduction and dealing with drug use and drug users
there are no concrete EU guidelines in place and policy is left up to the national
governments of individual countries. In this important area many existing EU member
states have adopted important measures designed to reduce the harm of official drug policy
but these practices are not proving to be so easily transferable to new member states. This
article discusses the consequences of failing to adequately develop policy across the EU in
this important area and suggests that failing to address this important issue in the new
member states could have far reaching ramifications for the rest of Europe.
Introduction
On the 1st May this year the European Union (EU) opened its doors to ten new
member states in its largest ever expansion. Eight of the acceding countries are
Central and Eastern European Countries (CEECs): the Czech Republic, Estonia,
Hungary, Latvia, Lithuania, Poland, the Slovak Republic and the Republic of
Slovenia. Cyprus and Malta were also successful in their applications and joined
the eight CEECs as new members of the EU. On 16th April 2003 negotiations with
these ten countries were completed and the Treaty of Accession was signed in
Athens. In addition, Bulgaria and Romania are expected to join in 2007, while
Turkey’s application currently remains subject to continuing negotiation. The
new member states are known as acceding countries while Bulgaria, Romania
(also CEECs) and Turkey remain candidate or attendant countries.
This has been the fourth process of enlargement entered into by the EU. The
original six members of the European Community (France, Germany, Austria,
Belgium, Luxembourg and the Netherlands) were joined in 1973 by Britain,
Denmark and Ireland, in 1981 by Greece, and, in 1986, by Spain and Portugal.
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Each time the EU has expanded its borders it has had to balance the positive
elements of enlargement against the negative ones. Greater general co-operation
and harmony across Europe, increased membership and increased international
influence and trading power must be weighed against the negatives of having to
find agreement among an increased number of national governments and the
possibility of having to support, mainly economically but also socially and
politically, less well-developed or less stable countries.
The issue of support has been particularly important to the 2004 enlargement
process as all of the ten acceding countries (as well as the remaining candidate
countries) are potentially less stable than existing member states. In particular, the
CEECs have experienced considerable political, economic and social changes and
are still dealing with the consequences of the break-up of the former Soviet Union
and the war in Yugoslavia. Negotiations with the acceding countries before their
acceptance were therefore stringent and in many cases have been proceeding
since the early 1990s.
EUROPA, the official Internet site of the European Union (2003), states that in
order for candidate countries to be accepted into the EU they must meet three
basic criteria: (1) they must be a stable democracy; (2) they must operate a
functioning market economy; and (3) they must agree to adopt the common
rules, standards and policies that make up the existing EU, collectively known as
the ‘Acquis Communautaire’. The final point, accepting the Acquis Communautaire,
has been the most time consuming as EU authorities have had to ensure that
appropriate legislation and policy frameworks were in place in acceding countries
for all issues dealt with at some level by the EU. For the purposes of this article the
preparations and practices of the acceding countries in relation to drug policy will
be examined. This has been shown to be an important issue at the European level,
but it is also an area where the supremacy of national control has been declared.
There is, therefore, no simple body of existing law and practice that can be
adopted by the acceding countries, yet it is an issue that has been prioritized in
the accession negotiations.
Throughout the 1980s and early 1990s the European Union made illicit drug
policy a priority as it tried to determine whether a liberal or restrictive policy was
a more appropriate and successful response to the drug problem. Despite the
appointment of two commissions in this area, EU opinion on the subject remains
hopelessly divided (Blom & van Mastrigt, 1994; Chatwin, 2003), particularly
regarding drug use and drug users, and illegal drug policy has since been
declared an area of subsidiarity (ultimately subject to national rather than inter-
national control). One area of agreement between existing member states is the
treatment of international drug traffickers. In this area minimum penalties for
drug trafficking offenders have been introduced across Europe (Oostlander, 2001)
and international co-operation has been engendered in the form of EUROPOL,
although it is questionable whether either of these two implementations has
achieved their full potential. The rest of drug policy is the domain of national
governments operating within the general guidelines of the European Union
Action Plan on Drugs (2000–2004).
Despite the lack of a cohesive European drug policy this issue has played an
important role in accession talks. As the enlargement process approached, the
Phare Programme was set up ‘to help applicant countries in their economic and
political transition to EU membership’ (Boekhaut van Solinge, 2002, p. 136). Illicit























































subgroup within the Phare project was set up exclusively for the purpose of
negotiating policy in this area. It was known as the Multibenificiary Drugs
Programme and was specifically created to manage the task of ensuring that
anti-drug measures already existing in EU member states were adopted by
candidate countries.
These anti-drug measures adopted by candidate countries tend to have been
prohibitive in nature and largely directed towards ‘drug detection, disrupting
drug supply channels, dismantling drug trafficking organizations and placing
drug traffickers under arrest’ (Phare Multibenificiary Drugs Programme, 2002,
pp. 1–2), as these are the major areas of consensus in European drug policy.
However, another trend has also recently been noted in European drug policy.
Within the existing EU member states there is a tendency to treat users of drugs
increasingly leniently and to adopt policy measures that aim to reduce the
amount of harm, in terms of health and social conditions, that are caused to
drug users.
These principles of ‘harm reduction’ have been widely in operation in Europe
since the 1980s and the perceived threat of an HIV epidemic. Their popularity
grew as fears of an HIV epidemic receded and every EU member state now
implements the exchange of dirty needles for clean ones and the provision of a
substitution treatment (e.g. methadone) for those addicted to heroin. This trend
towards leniency has been noted in many countries. Coffee shops providing a
legal outlet for cannabis sales have long been in operation in the Netherlands;
Portugal has recently decriminalized possession of all drugs for personal use and,
earlier this year, cannabis was downgraded from a Class B to a Class C offence in
Britain. However, it is by no means universal. In Sweden, for example, the aim
of a drug-free society is still ardently pursued by the national government and
to this end it targets drug users as much as drug dealers or drug traffickers
(Tham, 1998).
In the field of drug policy, concerns relating to accession have traditionally
surrounded the increased opportunities for drug trafficking and producing. To
counter these concerns trafficking and producing have been key issues in
negotiation talks with acceding countries and the EU have been able to impose
policy they have developed in this area (e.g. minimum penalties). Concerns have
also been raised that the level of information exchange that exists on the drug
problem within the EU may be disrupted by the accession of ten new, less well-
developed, member states. Well-established EU practices in this area, which have
already been extended to the acceding countries, should prevent this from
happening. Finally, drug policy in the new member states may diverge from
the general tendency towards harm reduction and tolerance towards drug use
and drug users recently observed in the existing EU. This is an area in which
official EU policy does not exist and particular strategies can only be presented in
advisory or guiding terms.
The EMCDDA (2003a, p. 1) have acknowledged that ‘the arrival of 10 new EU
Member States in 2004 may well fan the flames of an already complex EU drugs
problem’. This possibility will be explored first in relation to both the trafficking
and production of illicit drugs and the exchange of information on the prevalence
and patterns of drug use in Europe where existing co-operative standards are
well developed and international powers have invested a lot of time in trying to
ensure that these standards are extended to the acceding countries. Second, the
possibility will be explored in relation to the more complex issue of adhering to






















































the principles of harm reduction and tolerance towards drug use and drug users.
Standard European practice is not so well developed in these areas and initiatives
or strategies cannot be so easily imported. In addition, absorbing ten new
member states may have a considerable impact on the current balance between
liberalism and restriction over the drugs issue in general within the EU. These
issues will be discussed and the overall consequences, in terms of drug policy
within the EU, will be evaluated.
Trafficking and Production
Traditionally, in the illicit drug field, fears surrounding the accession of the ten
new member states to the European Union have been primarily directed at the
increased possibilities for trafficking and producing illicit drugs. The expansion of
the EU has been perceived as a threat to the control of drug trafficking and
organized crime that has been prioritized and developed within the EU in recent
years. Dorn (1996) has speculated that new issues of crime and drug control will
be raised by the acceding countries. For the first time there is a possibility that
heroin will be cultivated within the borders of the EU, the external frontiers of the
EU will not be as secure from international drug traffickers and the exchange of
information and general co-operation in this area will not be as comprehensive.
To some extent these fears are justified. Poland has been identified as a
producer country of opiates (Ruggiero & South, 1995) and laboratories involved
in the production of amphetamine and/or other synthetic drugs have been found
in the Czech Republic, Estonia, Hungary, Latvia and Lithuania (EMCDDA,
2002a). Customs and border controls are not as sophisticated in the CEECs
making the EU’s external borders generally less secure. Further, the accession
of Cyprus has provided another cause for concern in this area. The position of
Cyprus in the eastern Mediterranean with access to Europe, Africa and Asia
makes it a likely through route for drug traffickers.
The evidence outlined above would suggest that these fears regarding an
increase in the trafficking in and production of illicit drugs within the EU are well
founded. However, these consequences of accession have long been anticipated
and prevention strategies and programmes have therefore been implemented.
Dealing with the trafficking of drugs is an area of strong cohesion within the EU
and all standards and practices have already been adopted by the acceding
countries prior to their accession. In addition, many countries have made the
prevention of the trafficking of illicit drugs an area of special attention and focus
within their national strategies. For example, the Slovak Republic has recently
altered its penal code to include more stringent control measures against drug
dealers and organized crime (Nociar, 2000).
Cyprus is a country in which drug taking, let alone drug trafficking, is relatively
uncommon but in a statement to the Twentieth Special Session of the United
Nations General Assembly on the World Drug Problem, Zackheos (1998, p. 1)
acknowledges that this is a situation which may change and states ‘we are
determined to confront the issue before it becomes a problem’. To this end
Cyprus has established a national committee for the prevention of trafficking and
use of illicit drugs, which will be responsible for the provision and co-ordination
of drug prevention activities. The Government has also launched a system of























































envisaged trafficking situation from developing. Efforts have also been made to
prevent the country from being used for money laundering (EMCDDA, 2003b).
The identification of fears relating to increased trafficking in and production of
illicit drugs in the EU has enabled prevention programmes to be put in place, on
paper at least, in a number of acceding countries. This, combined with the
minimum standards in this area that acceding countries have adopted through
the Acquis Communautaire, should, theoretically, prevent the impact of the
acceding countries on these areas from being too great. However, it is obviously
too early to attempt to assess the usefulness of these measures in practical terms
and it should not be forgotten that their implementation, even in existing EU
member states, has not been entirely unproblematic. At this stage it is difficult to
determine whether strategies that have been developed on paper and that have
been imported from western European countries, where policing methods are
well developed and the practice of international co-operation in apprehending
criminals is well established, will translate well to eastern European countries
where existing standards are, in all probability, not of the same calibre.
Information Exchange Between Member States
A second area of concern is the ability of the acceding countries adequately to
prioritize the importance of collecting information and statistics on the nature of
the drug problem within their own national borders, and to make this informa-
tion available outside their national borders. Support has always been found
within Europe for both restrictive and liberal elements of drug policy and, rather
than leading drug policy through a top-down approach, EU policymakers have
had to adopt a more balanced and scientific approach to the issue. In 1995 the
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was
founded with the intention of collecting and disseminating data regarding the
extent and nature of the drug problem across EU countries. The official role
of the EMCDDA is to conduct scientific research and undertake evaluations of
interventions that are in practice against the drug problem without offering
judgements on the moral or practical desirability of those interventions.
Each of the existing member states has a national focal point which reports to
the EMCDDA on the individual drug problem experienced in that country.
Information on, for example, the number of drug users, the number of problem
addicts and the number of intravenous drug users (IDUs) who are HIV positive is
collected using research methods that are as standardized as possible. This
information, as well as updates on national strategies, harm-reduction initiatives
and prevention programmes, is presented to the EMCDDA in the form of an
annual national report on the nature of the drug problem. The EMCDDA then
uses this information to compile an annual report on drugs in the EU. In theory,
these reports provide a facility for comparing strategies, learning about new
trends and initiatives and spotting potential problems before they become Europe
wide.
However, the usefulness of these reports can be brought into question. It is
difficult to make accurate comparisons based on statistics developed using
different methods, collected at different times and presented in different ways,
despite standardizing procedures. Galtung (1990, p. 107) has documented the
difficulties of compiling data when ‘transcending geography and history’ and
dealing with ‘structural and cultural diversity’. These difficulties may mean that






















































the EMCDDA statistics are relatively useless in terms of pinpointing either
problem areas or particularly productive strategies, and in reality are more of a
concerted effort to focus on co-operation in sharing information rather than in the
more controversial area of actually implementing drug policy. Nevertheless, the
EU views the ability to participate in this information exchange of paramount
importance and, as such, the acceding countries must demonstrate their ability to
meet these requirements. In fact, the EMCDDA has been preparing for the
accession for some considerable time and has collected a fairly substantial amount
of information on drugs in the acceding countries.
Since 2001 the EMCDDA has been collecting information on the extent and
nature of the drug problem in the CEECs. For the last two years an Annual Report
on the Drug Situation in the CEECs has been produced alongside the Annual
Report of the existing EU member states. The information in this report mainly
focuses on the ten CEECs (including Bulgaria and Romania neither of which are
due to join the EU until 2007), but also contains limited information about the
situation in Cyprus and Malta. National focal points have been set up in the
CEECs for some time and, much more recently, have also been installed in
Cyprus and Malta. Information on the nature of the drug problem is not
well advanced in any of these countries and only relates to the very recent
past, but there is some reason to believe that its quality will grow and it will
continue for the foreseeable future, at least to the standards adopted by the
EMCDDA to date.
A secondary concern noted in this area surrounds the commitment of the
acceding countries to the continued development and advancement of illicit
drug policy now that the accession talks are over. The most recent Annual
Report on the candidate and acceding countries notes that all acceding countries
now have national drug strategies that are either in place or are in the final
stages of development. ‘All acceding and candidate countries have been active
in the legislative field since 1990 . . . [National strategies] tend to be compre-
hensive, centrally co-ordinated and orientated towards a global long-term
approach, and some are also structured to monitor performance’ (EMCDDA,
2003b). However, at this stage, it is difficult to assess, in real terms, how much
enduring influence such largely hypothetical strategies will have. They may be
full of good intentions but it is by no means certain that these intentions will
translate into practice.
Most of the national drug strategies developed by the acceding countries, and
in particular the CEECs, are influenced to some extent by the EU Action Plan on
Drugs (2000–2004). They therefore contain similar aims and objectives. For
example, Lithuania aims to prevent drug abuse among young people, reduce
drug supply and care for drug addicts (Phare Project on Drug Information
Systems, 2000a). Similarly, Poland aims to increase both access to health and
rehabilitation services and, for young people in particular, preventive measures
(Sieroslawski et al., 2001). This may be evidence of the acceding countries’ real
commitment to building comprehensive drug policies that are inherently
comparable with western European ones. Equally, it may only be evidence
of excessive political rhetoric surrounding these areas without the necessary
accompanying sentiment and deeper commitment.
Putting aside the doubts surrounding the usefulness and validity of the
collation of information by the EMCDDA and the development of national























































revealed by the work already completed on compiling the annual reports for the
CEECs. Eastern European countries have traditionally been seen as transit
countries in relation to illicit drugs. Drugs were either produced there or, more
often, produced outside but then brought to eastern European countries in
preparation for being smuggled into the west (Dorn, 1996). However, the actual
consumption rates of illicit drugs in the east were thought to be far below those in
the west. The 2003 Annual Report on the Acceding and Candidate Countries,
however, charts the growing prevalence of drug consumption within CEECs and
documents evidence that trends similar to those existing in the current EU are
developing. For example, cannabis has emerged as by far the most popular drug
of consumption and heroin as the drug most associated with problematic use in
the CEECs (EMCDDA, 2003b). This mirrors the current situation in existing EU
member states. This phenomena can be observed at a national (Slovenia) as well
as international level: ‘the continuing upward trend in the misuse of illegal drugs
has been noticed since 1986 . . . The drug that causes most problems is heroin,
but the most popular is cannabis’ (Rihtar, 2001, p. 17).
Harm Reduction
Both the areas of trafficking and production and of the collation and exchange of
information are ones in which the accession of ten new member states have
inspired concerns. However, the evidence presented above suggests that the
standards and guidelines the acceding countries have been forced to adopt,
together with the national strategies and focal points that they are developing, are
going someway towards addressing these concerns. Existing European policy is
strong and relatively well developed in these areas ensuring its easy theoretical
transfer to the acceding countries, although, as stated, it remains to be seen how
easy this will be in practice.
Harm reduction is an ethos to which all existing EU member states have
subscribed to a greater or lesser extent. The idea of reducing the harm caused to
drug users, particularly in terms of their health, gained popularity in the 1980s
under the threat of an HIV epidemic. Harm reduction has since become associ-
ated with the avoidance of the predicted epidemic and measures such as needle
exchange and substitution treatment are practiced in all existing EU member
states. However, no official standards and practices exist in this area. In the
Netherlands, commitment to harm reduction strategies is high and a policy of
normalization whereby drug users are accepted as a normal part of society and
drug policy initiatives try to reach out to these people rather than isolating them
has been adopted. Meanwhile, countries like Italy and Sweden have adopted
minimal harm-reduction initiatives preferring to keep the main focus of their
national strategies on prevention in their fight for a drug-free society. The
treatment of drug use and drug users is obviously an area that firmly comes
under national control and, as such, there is no existing framework to pass on to
the acceding countries. With the health of the population of Europe at stake this is
an important issue and its development in the acceding countries will have
implications for the health of Europe as a whole.
Another area where the drug policy of the acceding countries may diverge
from that commonly practiced in the EU is that of policy directed towards drug
use and drug users. Again there is no consensus in this area within the EU, but a
trend towards tolerance in response to drug use and drug users has been noted






















































(EMCDDA, 2002b). This trend may be loosely connected to the ethos of reducing
the harm caused by drug use but does not seem to have transferred to the
acceding countries. ‘Where legal attitudes to drugs are concerned some countries
have tended to criminalize the possession of drugs for personal use and/or drug
use per se since 1990. This contrasts with more recent drug law modifications in
some EU countries, which have addressed this question quite differently’
(EMCDDA, 2003a, p. 3). Cyprus and Malta have both criminalized drug use,
Fridli et al. (1994) have commented on the domination of legal control in
Hungary, and in Latvia (Phare Project on Drug Information Systems, 2000b)
and Malta (Muscat, 2000) no formal distinction is made between users, dealers
and traffickers. Again the differences in this area between trends observed
amongst existing EU members and those observed amongst acceding countries
may have important consequences.
As stated previously, the membership of ten new member states to the EU will
both extend its external borders and increase its internal space open to the free
movement of EU citizens. The increased opportunities for drug trafficking that
this entails have been noted and policy making in this area has been a focus.
However, the increased opportunity for the free movement of European citizens
could also incur problems in relation to illicit drug use. Dorn & White (1994) have
suggested that the free movement of persons has the potential to enhance the
spread of diseases such as HIV and hepatitis B and C, as well as making it harder
to meet the specific needs of migrant communities such as drug users. The
situation they fear is that problem drug users from new member states will
migrate to existing member states where harm-reduction measures are more
advanced, illicit drugs are more widely available and drug use is treated more
leniently. Further problems may then be encountered if these migrant drug users
are not viewed as eligible for assistance and are denied access to services by local
authorities. ‘Localities are ill equipped to resolve a problem of international
dimensions. They all too easily fall back on solutions which encourage the
exclusion of outsiders’ (Dorn & White, 1994, p. 232).
Some considerable effort has been made to ensure the development of harm-
reduction measures in the acceding countries. The reduction of drug-related
harm is one of the main objectives in the EU Action Plan on Drugs (2000–2004)
and this has translated into many of the national strategies in the acceding
countries. In particular, a policy of harm reduction has been pursued in the
national strategies of the Czech Republic and the Republic of Slovenia. One of the
goals of the national strategy in the Czech Republic is ‘to help drug addicted
persons to survive and minimize damage of their health and social condition . . .
to protect society against negative impacts of drug use, including blood-trans-
mitted diseases’ (Government of the Czech Republic, 2000, p. 25). In the Republic
of Slovenia harm-reduction initiatives such as the development of regional
centres for the prevention and treatment of drug addictions, workshops for
young people and voluntary work have been implemented (Rihtar, 2001). Aims
and initiatives such as these represent a good start in terms of implementing
harm-reduction measures but their continued development and funding is in
question now that the pressure is off and the candidates have acceded to the EU.
Furthermore, interventions are not so advanced in the rest of the acceding
countries. All of the CEECs have some needle exchange and substitution treat-
ment available, although this is often severely limited (EMCDDA, 2002a). Cyprus























































warned that ‘although all 10 CEECs have now implemented preventive and
harm-reduction measures, provision and coverage are too limited in most of
them . . . some measures—especially syringe and needle-exchange programmes
and methadone substitution—remain controversial’. If the attention given to
the continued development of drug policy in this area is not as extensive as
in policy against trafficking, producing and collating information then the
consequences for Europe, as well as for the acceding countries, could be dire.
The main concern here is that a failure to ensure the adequate development of
harm-reduction measures in the acceding countries could allow an HIV epidemic
to develop that may threaten the whole of Europe. The information on drugs in
the acceding countries suggests that the drug problem is progressing along
similar lines to the problem in western Europe, although some ten to fifteen
years behind. While the danger of an HIV epidemic in the west has faded into the
background it could be of imminent concern in the acceding countries. Indeed,
there is evidence to show that this is the case. The EMCDDA (2003a, p. 1) has
warned that ‘some east European countries are ‘‘threatened by the most rapidly
developing HIV epidemic in the world’’’.
The HIV problem is worst in Estonia and Latvia (EMCDDA, 2003b); in Estonia
486 new HIV positive cases were reported in the period from 1988 to 2000
(Estonian Institute of Experimental and Clinical Medicine, 2001). Even countries
like the Czech Republic with good harm-reduction records have been proved to
be deficient in this area. The Drug Law and Health Policy Resource Network
(2001) states that one area in which harm reduction is not so well developed in the
Czech Republic is towards AIDS and HIV-suffering drug addicts, who are often
forced to keep their illness a secret and live in isolation. In the acceding
countries—apart from Estonia and Latvia—levels of HIV are fairly low
(EMCDDA, 20003b) but a variety of reasons have been put forward by the
EMCDDA (2003b) for the possibility of an HIV epidemic in the near future.
These include geographical proximity to areas of high HIV prevalence, preva-
lence of socially marginalized groups, lack of awareness of the danger of HIV and
of access to clean injecting materials, police responses to syringe possession, lack
of HIV prevention policies and economic and social factors such as margin-
alization and stigmatization of addicts. The EU can encourage acceding countries
to develop policies in these areas but it cannot ensure that they do so, because
no official EU harm-reduction policy exists.
Discussion
The lack of consensus in the fields of both harm-reduction practices and treat-
ment of drug use and drug users within the European Union may well be
problematic for the development of both drug policy and the drug problem
within Europe. Where there is clear consensus within the EU, for example in the
treatment of drug traffickers, concrete policy initiatives can be directly transferred
to the acceding countries: in this case minimum penalties for drug addicts. Where
there are well-organized and developed standards and practices, for example in
the collation and dissemination of data on the European drug problem, these can
be implemented in the acceding countries. Early evidence shows that these issues
have already, to a large extent, been carefully considered in the acceding
countries and continuing efforts are being made to further the development of
policy in these areas. However, this evidence must be interpreted with a certain






















































degree of caution due to the lack of opportunity to evaluate the effectiveness of
these strategies in practice to date.
Dealing harshly with drug traffickers and compiling up-to-date information on
the drug situation are goals that all EU member states can agree on regardless of
the relatively restrictive or liberal nature of their national drug policy. However,
where consensus does not exist among EU member states, for example in the
treatment of drug use and drug users or the extent of harm-reduction measures to
be implemented, no clear transferral of policy can be extended to the acceding
countries. In its role as a scientific research centre the EMCDDA can encourage
the development of certain responses but it cannot enforce practices such as
leniency towards drug use and drug users when these ideas are not subscribed to
by all existing EU member states. While harm-reduction measures such as needle
exchange and substitution treatment, which are standard across the EU, have
been developed in all acceding countries, the EMCDDA can only recommend
the development of measures such as low-threshold services, drop-in centres,
outreach work or street-level nursing.
In some candidate countries HIV prevalence rates are reaching near epidemic
proportions (EMCDDA, 2003b). If harm-reduction measures are not nurtured this
situation may become a crisis in a way that was avoided by western Europe in the
1980s. The policy initiatives transferred in the case of harm reduction (i.e. needle
exchange and substitution treatment) have not been well developed so far and
there is very little in place to oversee their continued or further development. The
nature of the drug problem in most of the acceding countries is becoming
westernized and if harm-reduction services are not well developed in these
countries many problematic drug users could resort to moving to more tolerant
countries within the EU. Therefore, if harm-reduction strategies are allowed to
lapse in importance the danger of an HIV epidemic, starting in central and
eastern Europe, but eventually spreading across the majority of the EU, is very
real. Hommes & van der Vleugel (1993, p. 7) have commented on the con-
sequences of increased mobility and enlargement on the spread of HIV: ‘People
from regions with low HIV prevalence move to countries with high HIV
prevalence, and vice versa; tourists from epidemic centres travel to places
where HIV is still very rare and the other way round’. The increased mobility
of problematic drug users inspired by a lack of services in their own countries
holds a very real possibility of jeopardizing the low levels of HIV currently
experienced in many western European countries—especially where migrant
drug users are denied services in existing member states.
In the past, problems with the migration of drug users have occurred within
the original fifteen member states of the EU. In the 1990s policymakers in the
Netherlands and Germany argued over the high number of German citizens that
were living in the more tolerant Netherlands to support their drug habits.
German officials viewed the Netherlands as providing an attractive place for
German drug users to live and satisfy their addictions. Researchers have com-
mented (Boekhaut van Solinge, 1999) that Germany’s repressive drug policy was
pushing German drug users into the Netherlands more strongly than the liberal
Dutch policy was actually pulling them there. More recently, Germany’s drug
policy has become less repressive and has focused more strongly on the treatment
and understanding of addicts, resulting in far fewer German drug addicts moving
to the Netherlands. The lesson for the EU as a whole is that avoidance of a similar























































illicit drug policy that meets the needs of problematic drug users as well as
conforming to minimum standards in relation to trafficking and production.
The problems discussed above are serious and have implications not only
for the acceding countries but also for the rest of Europe. The EU has acknowl-
edged the need to be vigilant for the development of further problems relating to
drug policy in the acceding countries. ‘In a region undergoing such rapid change
. . . early detection of new trends and emerging problems will be of vital import-
ance, as will reacting quickly when new problems are identified’ (EMCDDA, 2003,
p. 3). It must ensure that the detection of new trends and emerging problems
remains a priority if an HIV outbreak and the mass migration of eastern European
problem drug users are to be avoided. The similarity of the drug problem in
eastern Europe with the situation in western Europe 10–15 years ago has been
discussed. It is important that attitudes towards these areas do not also remain
10–15 years behind western Europe if unpleasant consequences in terms of health
and the mass migration of drug users are to be avoided.
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